drugset / Trial / NCT05479487
Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma (including patients previous treated with a PARP inhibitor).
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-11-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluzoparib | Small molecule | 100 mg | — |
| Comparator | Fluzoparib | Small molecule | 150 mg | — |
| Subject | Rivoceranib | Small molecule | 375 mg | — |
Indications
No indication recorded.